Modified citrus pectin is a citrus fiber reshaped so the body absorbs part of it, blocking a protein tumors use to spread and evade immunity. Lab evidence is consistent; human evidence is thin, strongest for slowing a rising prostate marker in small uncontrolled studies. Low-toxicity, mostly digestive side effects — best seen as experimental, not a proven treatment. (Full Review)

Protocol

Dose

15 g/day

PectaSol-C powder, 5 g three times daily in water

Form

Powder

Dissolved in water; capsules deliver less

Timing

Split, away from food

Three doses across the day, away from meals and medications

Time to effect

PSA response

6–18 months

Biomarker change assessed over months, not days

Benefits

Medium: Slowing PSA progression in biochemically relapsed prostate cancer

Low: Reduced metastasis and tumor-cell adhesion; immune activation via natural killer cells

Speculative: Sensitization of tumors to chemotherapy and radiotherapy; activity across other solid tumor types

Contraindications

Bowel obstruction or severe gastrointestinal motility disorders

Pregnancy and lactation

Key Interactions

Narrow-therapeutic-index oral drugs (levothyroxine, digoxin, warfarin)

Oral iron salts, mineral-containing antacids

Mineral supplements (calcium, iron, zinc, magnesium)

Other galectin-3 or metal-binding agents (alginates, other modified pectins)

Chemotherapy or radiotherapy

Risk & Side Effects

High: Gastrointestinal discomfort

Medium: Substitution for evidence-based cancer treatment

Low: Product contamination and heavy-metal exposure; reduced absorption of minerals and oral medications

Speculative: Unknown long-term effects of sustained galectin-3 blockade

Monitoring

Marker	Target	Why
Galectin-3 (serum)	< 14 ng/mL	Tracks the intended target and inflammatory/fibrotic burden
PSA	Individualized; falling or stable trend	Primary response marker in prostate cancer
PSA doubling time	Lengthening (longer is better)	Main efficacy readout in relapsed prostate cancer
Iron studies (ferritin)	Ferritin ~50–150 ng/mL	Detects mineral depletion from high-dose fiber
Blood lead level	< 3.5 µg/dL	Screens for heavy-metal contamination from the product
C-reactive protein (CRP)	< 1.0 mg/L	General marker of inflammation the intervention may influence

Cadence: PSA every 1–3 months; galectin-3 every 3–6 months; mineral status and safety labs every 6–12 months

Qualitative Assessment

Digestive comfort (bloating, gas, stool consistency) as a tolerability signal
Energy levels and general sense of wellbeing
Appetite and weight stability
For prostate cancer, absence of new symptoms (bone pain, urinary changes)

Modified Citrus Pectin to Treat Cancer

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment